Ocular Therapeutix Reports Q3 2026 Results, $530.6 Million Cash Balance
Ocular Therapeutix reported Q3 2026 revenue of $12.9M, a net loss of $94.8M, and $530.6M in cash. The company plans to submit AXPAXLI NDA for wet AMD in Q4 2026, with topline results expected in Q1 2028. Research and development expenses increased to $74.8M from $52.4M a year earlier.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but the cash runway supports continued R&D and could enable future financing or partnership opportunities.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders monitoring ophthalmology sector and cash‑rich biotech balances.
What to watch
Potential partnership or licensing deals for AXPAXLI are not disclosed but could materially improve outlook.
Background
Ocular Therapeutix filed an 8‑K reporting its Q3 2026 earnings and cash position, and provided updates on its AXPAXLI NDA and trial timelines.
Ticker impact
Q3 2026 results show revenue $12.9M, net loss $94.8M and $530.6M cash, with AXPAXLI NDA on track for Q4.
likely downward pressure as market prices in the larger loss and revenue decline
The company posted a loss that widened year‑over‑year and revenue fell, which historically drags biotech stocks, while the cash runway is ample but does not offset earnings disappointment.
Market effects
May weigh on ophthalmology biotech peers as trial timelines remain unchanged but financial results are weak.
Limited to US biotech sector; no broader market effect.
Low; impact confined to niche eye‑disease therapeutic space.
Counterpoint
The sizable cash balance could fund upcoming trial milestones, offering a catalyst for upside if data are positive.
Key entities
- companyOcular Therapeutix, Inc.
US‑listed ophthalmology biotech (ticker OCUL) reporting Q3 2026 results.
- drug_candidateAXPAXLI
Investigational therapy for wet AMD, NDA submission planned for Q4 2026.




